Bohui Shi

Association of neoadjuvant subcutaneous trastuzumab with higher pathological complete response in HER2-positive breast cancer: a real-world doubly robust study

Randomized trials have demonstrated the non-inferiority of subcutaneous (SC) versus intravenous (IV) trastuzumab. Its association with pathological complete response (pCR) in routine neoadjuvant practice warrants further study. The ability of serial ultrasound measurements to dis...